Eli Lilly ‘commends’ ITC ruling cracking down on unlawful tirzepatide imports

Eli Lilly (LLY) stated: “In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs and Border Protection should prevent the illicit import of knock-off tirzepatide products. The ruling is based on the finding that multiple bad actors importing or selling imported knockoff ‘tirzepatide’ were likely to deceive consumers about the nature and source of their products. Seven entities-located in China, Spain, Texas, Florida, and Iowa-were found to violate federal law because their conduct was likely to deceive consumers about whether their imported ‘tirzepatide’ products were genuine Lilly medicines, and by falsely claiming they had undergone clinical trials, were FDA-approved, or even contained tirzepatide when they did not. The ruling applies to anyone importing illicit knockoff tirzepatide products.”